Market Mover: Poseida (PSTX) Rises at Midday June 22

Equities Staff  |

Today Poseida Therapeutics Inc (NASDAQ: PSTX) is trading 5.50% up.

The latest price, as of 12:08:09 est, was $2.11. Poseida has climbed $0.11 so far today.

137,671 shares exchanged hands.

As of the previous close, Poseida has a YTD change of 70.63%. The company expects its next earnings on 2022-08-11.

For technical charts, analysis, and more on Poseida visit the company profile.

About Poseida Therapeutics Inc

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core proprietary platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Its core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable Poseida Therapeutics to engineer its wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

To get more information on Poseida Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Poseida Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content